Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196159 | 0.83 | TSHR (0.52) | GAATSHRLTB4RLMNAALDH1A1 | |
| SCHEMBL7313785 | 0.81 | GAA (0.47) | GAATSHRLTB4RLMNAALDH1A1 | |
| SCHEMBL20551619 | 0.80 | GAA (0.43) | GAATSHRLMNAALDH1A1MAPT | |
| SCHEMBL17173944 | 0.80 | TSHR (0.46) | GAATSHRLMNAALDH1A1MAPT | |
| SCHEMBL11544700 | 0.75 | LRRK2 (0.50) | GAATSHRLMNAALDH1A1LRRK2 | |
| SCHEMBL7311064 | 0.75 | HPGD (0.43) | GAATSHRLMNAALDH1A1MAPT | |
| SCHEMBL31194569 | 0.75 | GAA (0.55) | GAATSHRLMNAALDH1A1LRRK2 | |
| SCHEMBL2073225 | 0.74 | MAPT (0.55) | GAATSHRLMNAALDH1A1LRRK2 | |
| SCHEMBL8694634 | 0.74 | GAA (0.40) | GAATSHRLMNAALDH1A1LRRK2 | |
| SCHEMBL17173942 | 0.73 | LMNA (0.56) | LMNAALDH1A1MAPTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8598200-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073143-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | GAA 335/4885TSHR 3792/4885LTB4R 203/4885 |
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | GAA 750/4885TSHR 1205/4885LTB4R 2846/4885 |
| US-20120302599-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | GAA 750/4885TSHR 1205/4885LTB4R 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.